Literature DB >> 16981826

The role of nitric oxide in mediating tumour blood flow.

George Van Buren1, E Ramsay Camp, Anthony D Yang, Michael J Gray, Fan Fan, Ray Somcio, Lee M Ellis.   

Abstract

Nitric oxide (NO) is a ubiquitous molecule with a myriad of physiological and pathophysiological roles. It has numerous direct and indirect effects on tumour vasculature as both a regulatory and effector molecule. NO affects tumour blood flow through its effects on tumour angiogenesis, vascular tone and vascular permeability, partly via its interaction with vascular endothelial growth factor. In this review, the authors examine the basic tenants of NO biology, the association of NO with tumour progression, and the role NO plays in mediating alterations in vascular functions in tumours.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16981826     DOI: 10.1517/14728222.10.5.689

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  5 in total

1.  Inhibition of endothelial nitric oxide synthase decreases breast cancer cell MDA-MB-231 adhesion to intact microvessels under physiological flows.

Authors:  Lin Zhang; Min Zeng; Bingmei M Fu
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-04-08       Impact factor: 4.733

2.  STAT3-iNOS Signaling Mediates EGFRvIII-Induced Glial Proliferation and Transformation.

Authors:  Sidharth V Puram; Caleb M Yeung; Arezu Jahani-Asl; Chieyu Lin; Nuria de la Iglesia; Genevieve Konopka; Laurie Jackson-Grusby; Azad Bonni
Journal:  J Neurosci       Date:  2012-06-06       Impact factor: 6.167

3.  Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow.

Authors:  Jeff S Isenberg; Fuminori Hyodo; Lisa A Ridnour; Caitlin S Shannon; David A Wink; Murali C Krishna; David D Roberts
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

4.  Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls.

Authors:  J E Bohonowych; U Gopal; J S Isaacs
Journal:  J Oncol       Date:  2010-06-24       Impact factor: 4.375

5.  A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis.

Authors:  John C McAuliffe; Kelly K Hunt; Alexander J F Lazar; Haesun Choi; Wei Qiao; Peter Thall; Raphael E Pollock; Robert S Benjamin; Jonathan C Trent
Journal:  Ann Surg Oncol       Date:  2008-10-25       Impact factor: 5.344

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.